Lawsuit a Catalyst for LDT Regulation Progress?

We have written extensively about health system regulation in this blog, with a keen interest in how LDT regulation will shake out.  In our other blog we’ve even argued strongly for caution in LDT regulation, primarily to avoid stifling innovation.  However, our...

Chart of the Week: Alzheimer’s Biomarker and Trial Landscape

This week’s CotW includes the landscape of biomarkers and clinical trials for Alzheimer’s disease.  There is significant clustering around two biomarkers, but many interesting emerging biomarkers in clinical trials. Gray: Disease Blue: Biomarkers...

Precision Medicine Innovation Not Just a Numbers Game

We published a revision to our Precision Medicine Scorecard: Drug Company Edition last month. As John Audette rightfully notes, there are multiple factors in a pharmaceutical company’s contribution to precision medicines: How many precision medicines a company...

Chart of the Week: Celgene Precision Medicine Activities Graph

We’ve been curious about Celgene’s activity in precision medicine for some time.  We’ve posted blog posts here, here and here proposing that Celgene’s activities are indicative of a precision medicine push.  As a supplement, this weeks CotW is...

Biomarker Panels Explode in LDTs

In this blog we have regularly assumed (without hard data until now) that most biomarker innovation was taking place in laboratory-developed tests (LDTs) as opposed to tests cleared and approved by FDA, and we can now confirm that this assumption is correct. Now that...